Rapid eye movement sleep behaviour disorder: Past, present, and future

Högl, Birgit; Arnulf, Isabelle; Bergmann, Melanie; Cesari, Matteo; Gan‐Or, Ziv; Heidbreder, Anna; Iranzo, Álex; Krohn, Lynne; Luppi, Pierre‐Hervé; Mollenhauer, Brit; Provini, Federica; Santamaría, Joan; Trenkwalder, Claudia; Videnović, Aleksandar; Stefani, Ambra

doi:10.1111/jsr.13612

Cited by 17 publications

(9 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glutamatergic neurons located within the microcerebellar pontine nucleus on the ventral side of the laterodorsal tegmental nucleus [sublaterodorsal tegmental nucleus (SLD) in rats and the locus subcoeruleus in humans] are responsible for inducing hypotonia during REM sleep [ 5 ]. These experiments [ 6 ] showed that GABA glycine neurons located on the ventral side of the medulla oblongata projected into motor neurons during REM sleep and hyperpolarized them, resulting in muscle weakness.…”

Section: Introductionmentioning

confidence: 99%

The treatment efficacy of pharmacotherapies for rapid eye movement sleep behavior disorder with polysomnography evaluation: A systematic review and meta-analysis

Que

Zheng

Zhang

et al. 2022

Heliyon

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

The treatment efficacy of pharmacotherapies for rapid eye movement sleep behavior disorder with polysomnography evaluation: A systematic review and meta-analysis

Que

Zheng

Zhang

et al. 2022

Heliyon

View full text Add to dashboard Cite

“…In fact, about 90% of patients with iRBD at 15 years of follow-up receive a clinical diagnosis of alpha-synucleinopathy, namely Lewy Body Dementia (DLB) in about 45%, Parkinson’s disease (PD) in 45%, and multiple system atrophy (MSA) in 5%. 7 , 8 …”

Section: Rbd In Neurodegenerative Disease a Window Into Prodromal Par...mentioning

confidence: 99%

“…Moreover, in managing RBD it is important to inform the patient about the association between RBD and neurodegenerative disorders and scheduling follow-up neurological examinations in order to early recognize any sign of synucleinopathies. 2 , 8 …”

Section: Rbd In Neurodegenerative Disease a Window Into Prodromal Par...mentioning

confidence: 99%

Considering REM Sleep Behavior Disorder in the Management of Parkinson’s Disease

Figorilli¹,

Meloni²,

Lanza³

et al. 2023

NSS

View full text Add to dashboard Cite

Rapid eye movement (REM) sleep behavior disorder (RBD) is the result of the loss of physiological inhibition of muscle tone during REM sleep, characterized by dream-enacting behavior and widely recognized as a prodromal manifestation of alpha-synucleinopathies. Indeed, patients with isolated RBD (iRBD) have an extremely high estimated risk to develop a neurodegenerative disease after a long follow up. Nevertheless, in comparison with PD patients without RBD (PDnoRBD), the occurrence of RBD in the context of PD (PDRBD) seems to identify a unique, more malignant phenotype, characterized by a more severe burden of disease in terms of both motor and non-motor symptoms and increased risk for cognitive decline. However, while some medications (eg, melatonin, clonazepam, etc.) and non-pharmacological options have been found to have some therapeutic benefits on RBD there is no available treatment able to modify the disease course or, at least, slow down the neurodegenerative process underlying phenoconversion. In this scenario, the long prodromal phase may allow an early therapeutic window and, therefore, the identification of multimodal biomarkers of disease onset and progression is becoming increasingly crucial. To date, several clinical (motor, cognitive, olfactory, visual, and autonomic features) neurophysiological, neuroimaging, biological (biofluids or tissue biopsy), and genetic biomarkers have been identified and proposed, also in combination, as possible diagnostic or prognostic markers, along with a potential role for some of them as outcome measures and index of treatment response. In this review, we provide an insight into the present knowledge on both existing and future biomarkers of iRBD and highlight the difference with PDRBD and PDnoRBD, including currently available treatment options.

show abstract

“…PSG is internationally conducted according to criteria defined by the American Academy of Sleep Medicine (AASM; Berry et al, 2015). (Ruoff & Rye, 2016) or REM sleep behaviour disorder (Högl et al, 2022;Riemann et al, 2017) require the conductance of PSG for diagnosis.…”

Section: Polysomnography -The 'Gold Standard' In Sleep Diagnostics?mentioning

confidence: 99%

The importance and limitations of polysomnography in insomnia disorder—a critical appraisal

Frase,

Nissen,

Spiegelhalder

et al. 2023

Journal of Sleep Research

View full text Add to dashboard Cite

SummaryThe importance polysomnography (PSG) in the diagnosis and treatment process of insomnia disorder (ID) remains highly disputed. This review summarises the state of the science regarding PSG indications and findings in ID, and the indications to conduct PSG in ID as stated by relevant guidelines. It then highlights the most relevant questions regarding the topic, including the relevance of ID subtyping, to allow an individualised pharmacological or psychotherapeutic treatment approach.

show abstract

Rapid eye movement sleep behaviour disorder: Past, present, and future

Cited by 17 publications

References 93 publications

The treatment efficacy of pharmacotherapies for rapid eye movement sleep behavior disorder with polysomnography evaluation: A systematic review and meta-analysis

The treatment efficacy of pharmacotherapies for rapid eye movement sleep behavior disorder with polysomnography evaluation: A systematic review and meta-analysis

Considering REM Sleep Behavior Disorder in the Management of Parkinson’s Disease

The importance and limitations of polysomnography in insomnia disorder—a critical appraisal

Contact Info

Product

Resources

About